AIM-listed clinical stage biotech company

1. AIM-listed clinical stage biotech company David Evans Dr Richard Goodfellow Professor Lindy Durrant 13th March 2012

2. Disclaimer This document is issued by Scancell Holdings plc (the “Company”), has been prepared solely for information purposes and is the sole responsibility of the directors of the Company. To the best of the knowledge and belief of the directors of the Company, who have taken all reasonable care to ensure that such is the case the information contained in this presentation is in accordance with the facts and does not omit anything likely to affect the import of such information. The dissemination of the information in these slides outside the United Kingdom may be restricted by law or regulations applicable in certain jurisdictions. This presentation does not constitute or form, and should not be construed as constituting or forming, part of any offer or invitation to sell, or any solicitation of any offer to purchase or subscribe for, any securities in the Company or any other body corporate or an invitation or inducement to engage in investment activity under section 21 of the Financial Services and Markets Act 2000 nor shall it or any part of it form the basis of or be relied on in connection with any contract therefore. No reliance may be placed for any purpose whatsoever on the information contained in this presentation or on assumptions made as to its completeness. Some of the statements in the presentation represent the personal opinions of the directors of the Company. No representation or warranty, express or implied, is given by the Company or Zeus Capital Limited (“Zeus”), any of its subsidiaries or any of their respective advisers, officers, employees or agents, as to the accuracy, fairness or completeness of the information, opinions or statements based on the belief of the directors of the Company contained in this presentation or expressed in the presentation and no liability is accepted for any such information or opinions or statements based on the belief of the directors of the Company (which should not be relied upon) or for any loss howsoever arising, directly or indirectly, from any use of this presentation or its contents or information expressed in the presentation. This presentation is directed only at persons in the United Kingdom who fall within either Article 19 (investment professionals) or Article 49 (high net worth companies) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended). Persons who do not fall within either Article 19 or Article 49 should not rely on, or act upon, any information contained in this presentation. This document does not constitute an offer of securities in the United States. Shares of the Company may not be offered or sold in the United States without being registered under the United States Securities Act of 1933, as amended (“U.S. Securities Act”) or an available exemption from such registration. The Company does not presently intend to register any securities under the U.S. Securities Act and no public offering of shares is being or will be made in the United States. The information contained in this document is not for publication or distribution in, into or from the United States, Canada, Australia or Japan. Any failure to comply with these restrictions may constitute a violation of United States, Canadian, Australian or Japanese securities laws. This presentation contains forward looking statements which relate, inter alia, to the Company's proposed strategy, plans and objectives.  Such forward looking statements involve known and unknown risks, uncertainties and other important factors beyond the control of the Company (including specific factors identified in this presentation and in our published Financial Statements) that could cause the actual performance, results, developments or achievements of the Company to be materially different from such forward looking statements.  Accordingly, you should not rely on any forward looking statements and the Company accepts no obligation to disseminate any updates or revisions to such forward looking statements.  By receiving this presentation you agree to be bound by the foregoing provisions.

3. David Evans Non- Executive Chairman

4. Dr Richard Goodfellow Co-Chief Executive

5. Company Overview • Clinical stage immunotherapy company with novel ‘ImmunoBody’ DNA vaccine platform for cancer and chronic infectious diseases • Lead product (SCIB1 for melanoma) entered Phase I clinical trials in June 2010 with steady progress made in 2011 -Dose increased from 0.4mg to 4mg with no serious adverse effects • Follow up vaccine targeting NY-ESO-1 (SCIB2) at pre-clinical proof of principle stage (lung, oesophageal, prostate, liver, gastric, ovarian, bladder cancers) with more in the pipeline • Partnerships with Ichor Medical Systems, immatics Biotechnologies GmBH and others to optimise immune response and generate new products • Antibody portfolio sale to Arana Therapeutics (now Cephalon/Teva) in 2006 Milestone payment of £2.85m received in November 2011 when SC104 started Phase 1 clinical trials in USA

6. Industry Trends • Continued trend for Big Pharma to move away from in-house R&D and to rely more on partnerships with Industry and Academia • Larger Biotechs becoming more aggressive buyers of innovative companies and providing growing competition for Big Pharma • Pick up in M&A deal value in 2011 (e.g. Amgen/Biovex $1 billion) • Public markets still generally unsupportive of early stage Biotech (until key value inflexion point reached) • Outstanding projects with future strategic value to third party will succeed

7. Cancer Vaccine Sales Increasing

8. A Year of Steady Progress • Patient recruitment for Phase 1 trial of SCIB1 in melanoma completed • Dose escalation to highest dose of 4mg achieved with no serious adverse effects • Follow up vaccine for lung and other cancers (SCIB2) produces outstanding results in animal studies • Additional £1.73m (gross) raised in June 2011 • Milestone payment of £2.85m received when SC104 entered clinical trials in November 2011 confirming commercial value of Scancell science • Significant additional progress on technology platform • Fully funded to completion of Phase 2 clinical trial

9. Share Information Listing on AIM October 2011 Placing £1.58m raised Milestone payment of £2.85m from Cephalon Inc received Share Price (10 for 1 Subdivision of Shares occurred 25 July 2011) Market Capitalisation at 1st January 2008- 2012 £1.6m raised in PLUS float April 2010 Placing £2.5m raised This data has been collated from information supplied by the London Stock Exchange, the PLUS Market and analyst research notes from the last four years

10. Strategy on Track • Validation of ImmunoBody platform through • - Clinical data on SCIB1 • - Phase 1 data 2012 • - Phase 2 data 2013 • - Pre-Clinical data on new ImmunoBody vaccines • - New supporting technologies • Trade sale to large pharmaceutical or biotech company

11. Professor Lindy Durrant Co- Chief Executive

12. SCIBI (melanoma) High avidity CD8 and CD4 response Better than synthetic peptide or whole antigen Better than DNA antigen immunisation Similar to DC vaccines Works with gene gun, id/im electroporation Induces anti-tumour activity in vivo GMP manufactured No Toxicity CTA May 2010 Clinical Trial June 2010 Metheringham et al., 2009 mabs

13. Ichor TRIGRID™ Delivery System Application Cartridge Integrated Applicator Electrodes Pulse Stimulator Figure 2. Injection Needle Uses electrical fields to increase DNA drug delivery efficiency Electrode array consists of four electrodes in a diamond-shaped grid around a central injection needle Simple hand-held device developed for use in humans Can deliver equivalent does in man to mouse Im easier to deliver in humans than id

14. Primary Objective: To demonstrate safety and tolerability Secondary Objective: To demonstrate cellular immune response (high avidity T-cells) and tumour response Phase One 9 patients 3 subjects per cohort; 0.4mg, 2.0 mg or 4.0 mg Progression only if adequate safety demonstrated at previous dose Phase Two 13 subjects Subjects to receive maximum tolerated dose provided no clear evidence of improved efficacy at lower doses Phase I-II trial in stage IV/III melanoma Start: June 2010 3wks 6wks 3 months 6 months 0

15. Phase I-II trial in stage III/IV melanoma • GTAC approval for the trial was given in May 2010 and the first patient was immunised in June 2010 • 5 centres: Nottingham, Manchester, Newcastle, Leeds and Southampton • Phase I fully recruited – no toxicity • Phase II starting 2 Q 2012 • Phase I completed by end 2012 • Phase II completed in 2013 with report in early 2014

16. Vaccine encodes 20 epitopes • covers 90-100% of population • Better than peptide • Better than Dc peptide (Dendreon) SCIB2-NYESO-1 • Expressed by lung (SCLC), melanoma, oesophageal, liver, • gastric, prostate, ovarian and bladder cancers • Improves survival P=0.044 In combination with homspera it completely inhibits tumour growth p=0.0041 p=0.0003 1E-10 1E-09 1E-08 1E-07 1E-06 1E-05

17. Candidate for SCIB3? • Novel patentable target (Patents being prepared) • Widely expressed ( lung , ovarian , renal, leukaemias, sarcomas, melanoma, oesophageal, liver, gastric and prostate cancers) • Novel CD4 self epitope stimulates killer CD4 T cells • Potent anti-tumour response

18. Summary • Phase I recruited • Phase II due to start April 2012 • SCIB2 NYESO-1 good anti-tumour response • SCIB3 new patent good anti-tumour response

19. Appendix

20. Board of Directors

21. Key Facts & Major Shareholders December 2011 *Oxford Technology Management Limited does not hold these Ordinary Shares directly but is the manager for the Oxford Technology VCT plc which holds 666,663 Ordinary Shares and Oxford Technology 3 VCT plc which holds 275,925 Ordinary Shares

22. Glossary